Geburtshilfe und Frauenheilkunde

LinksSchließen

Referenz

Bidard F-C, Jacot W, Dureau S. et al.
Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial.

Cancer Res 2019;
DOI: 10.1158/1538-7445.SABCS18-GS3-07.

Bibliographische Angaben herunterladen

Suchen in:

Aufrufen in: